[{"indications": "Indications\u00a0low blood volume (but \n(From Plasma substitutes: British National Formulary)\nPlasma substitutes)", "name": "GELATIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.2 Fluids and electrolytes", "9.2.2 Parenteral preparations for fluid and electrolyte imbalance", "9.2.2.2 Plasma and plasma substitutes", "Plasma substitutes", "GELATIN"], "cautions": "Cautions\u00a0\n(From Plasma substitutes: British National Formulary)\nCautions\u00a0Plasma substitutes should be used with caution in patients with cardiac disease, severe liver disease, or renal impairment; urine output should be monitored. Care should be taken to avoid haematocrit concentration from falling below 25\u201330% and the patient should be monitored for hypersensitivity reactions.", "side-effects": "Side-effects\u00a0\n(From Plasma substitutes: British National Formulary)\nCautions\u00a0Plasma substitutes should be used with caution in patients with cardiac disease, severe liver disease, or renal impairment; urine output should be monitored. Care should be taken to avoid haematocrit concentration from falling below 25\u201330% and the patient should be monitored for hypersensitivity reactions.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200800.htm", "doses": ["By intravenous infusion, initially 500\u20131000\u00a0mL\r\nof a 3.5\u20134% solution (see notes above)"], "pregnancy": "Pregnancy\u00a0manufacturer of Geloplasma\u00ae advises\r\navoid at the end of pregnancy"}]